Goldman Sachs Group Inc Syndax Pharmaceuticals Inc Transaction History
Goldman Sachs Group Inc
- $706 Billion
- Q2 2025
A detailed history of Goldman Sachs Group Inc transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Goldman Sachs Group Inc holds 5,797,195 shares of SNDX stock, worth $75.2 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
5,797,195
Previous 3,921,541
47.83%
Holding current value
$75.2 Million
Previous $48.2 Million
12.71%
% of portfolio
0.01%
Previous 0.01%
Shares
22 transactions
Others Institutions Holding SNDX
# of Institutions
250Shares Held
100MCall Options Held
1.28MPut Options Held
1.29M-
Kynam Capital Management, LP Princeton, NJ8.52MShares$111 Million9.53% of portfolio
-
Black Rock Inc. New York, NY7.91MShares$103 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.03MShares$65.3 Million0.0% of portfolio
-
Eversept Partners, LP New York, NY4.07MShares$52.7 Million3.84% of portfolio
-
Bank Of America Corp Charlotte, NC3.84MShares$49.8 Million0.0% of portfolio
About Syndax Pharmaceuticals Inc
- Ticker SNDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,565,200
- Market Cap $734M
- Description
- Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...